中國先鋒醫藥(01345.HK)公佈年度業績 市場覆蓋明顯提升 資產負債比率降至1.1%
格隆匯3月31日丨中國先鋒醫藥(01345.HK)公佈,截至2020年12月31日止年度,公司收益增加1.2%至人民幣13.32億元,毛利達6.08億元,末期股息每股港元0.075。公司資產負債比率於2020年12月31日為1.1%,於2019年12月31日為3.1%。
報吿期內,集團通過提供綜合性營銷、推廣及管道管理服務的醫療器械收益為人民幣1.66億元,較去年增加28.7%,佔集團於報吿期內收益12.5%。
報吿期內,集團營銷網絡的發展帶來市場覆蓋的明顯提升。比如戴芬新增覆蓋醫院和醫療機構5,332家,而希弗全新增覆蓋醫院583家。隨着醫藥市場環境的不斷變化,更為完善和健康的營銷網絡,是集團運營的重要基礎。
2020年,中國的藥品及醫療器械審批政策,繼續圍繞着國務院辦公廳《關於深化審評審批制度改革鼓勵藥品醫療器械創新的意見》的要求,不斷推進各項改革措施。尤其是優化臨牀試驗審評審批程式,接受境外臨牀試驗數據等,將有助於加快境外優質藥品及醫療器械產品在中國的上市進程。集團正積極保持與多個海外醫藥及醫療器械公司的緊密聯絡,以適時引進其具有潛力或市場基礎的產品以供營銷、推廣及銷售。
公司表示,集團將繼續圍繞產品開發引進、深度挖掘產品營銷及推廣能力、合作共贏擴大產品市場覆蓋、適時通過併購方式充實產業鏈這幾方面,在中國醫藥行業格局的變化中積極應對,鋭意進取,實現未來發展的新藍圖。與此同時,集團一直積極探索機會,為未來發展及業務拓展尋求有增長潛力的市場,亦為股東創造價值和提高回報。為此,集團一直處於尋找和探索具有廣闊的前景和機遇商業領域的過程中,包括在中國開展環保產業,同時堅持進行現有主要業務,以進口藥品及醫療器械的全面市場行銷、推廣和管道管理服務為核心業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.